eClinical Technology and Industy News

Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis

Excerpt from the Press Release:

CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis.

“We are pleased that dosing has begun in the Phase 2 trial to evaluate the potential of this novel product candidate to benefit people worldwide who are living with atopic dermatitis,” said Jonathan Zung, Ph.D., Chief Development Officer of Evelo. “Our previously released Phase 1b data, together with the positive results we recently released from our Phase 2 trial in mild and moderate psoriasis, demonstrate that EDP1815 has the potential to be a safe, effective, well tolerated, oral, inflammation resolving therapy.”

“Patients and prescribers are in need of a therapy that is safe and well tolerated, as well as orally delivered, for the treatment of atopic dermatitis” said Benjamin Ehst, M.D., Ph.D., Board-certified Dermatologist, Investigator and Clinical Associate Professor with the Oregon Medical Research Center, and Chief Investigator of EDP1815-207. “The integrated safety, tolerability, and efficacy data seen in the Phase 2 trial of EDP1815 in psoriasis, along with its oral administration and potential to be affordably priced, could provide meaningful change to the treatment paradigm for patients living with atopic dermatitis.”

Topline results from the Phase 2 clinical trial are expected in 1H 2023.

About the EDP1815 Phase 2 Clinical Trial
EDP1815-207 is a 16-week, multi-center, double-blind, placebo-controlled Phase 2 trial for the treatment of mild, moderate, and severe atopic dermatitis.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives